Exogenous lactate-ketone ester administration for appetite suppression and weight management
Mmimetika Biosciences proposes an innovative approach to weight management through exogenous lactate-ketone ester (LaKe) administration, shown to reduce appetite and slow gastric emptying, supporting weight loss. Clinical trials aim to validate these effects for potential EFSA Health Claim.
Overview
Mmimetika Biosciences is pioneering a novel approach to weight management by leveraging exogenous lactate-ketone ester (LaKe) administration. This solution mimics the effects of exercise and fasting, targeting appetite reduction and gastric emptying delay. Initial human clinical studies have demonstrated a significant appetite reduction of approximately 25% and extended gastric emptying time, which are conducive to weight loss. The core mechanism involves modulation of appetite-related hormones, including a decrease in ghrelin and an increase in satiety-inducing hormones such as LEAP2, GLP1, and Lac-Phe, with effects lasting up to four hours post-consumption.
Technical specifications
- Oral administration: More effective than parenteral routes, enhancing practicality and user compliance.
- Hormonal effects: Includes lowered ghrelin and increased LEAP2, GLP1, and Lac-Phe, promoting satiety and reducing hunger.
- Duration of effects: Hormonal modulation persists for at least four hours after intake, supporting sustained appetite suppression.
- Planned validation: A 12-week interventional clinical study with 40 participants, focusing on weight, muscle mass changes, metabolic health indicators, cardiovascular health, and cognitive parameters.
Technology readiness level
Currently at TRL 4, the solution has undergone basic validation in laboratory settings. The upcoming clinical studies aim to advance its readiness by establishing comprehensive clinical evidence, potentially leading to an EFSA Health Claim Dossier.
About Mmimetika Biosciences ApS
Mmimetika Biosciences ApS is a Danish biotechnology company that develops lactate-ketone (LaKe) ester dietary supplements designed to mimic the metabolic effects of intense exercise and fasting. Born from over 40 years of research at Aarhus University, the company created a novel, single-molecule ester that converts upon ingestion into both lactate and beta-hydroxybutyrate (BHB). This dual-metabolite approach distinguishes their product from conventional ketone supplements, allowing it to activate specific cellular pathways associated with metabolic stress and energy production without the need for excessive salt intake. The company utilizes a scientifically grounded approach to support metabolic health and cellular signaling.
The organization is focused on commercializing its technology for various health applications, including recovery, metabolic control, cognitive health, and cardiovascular support. Mmimetika has transitioned from clinical validation toward commercial scale, pursuing regulatory pathways such as U.S. GRAS compliance and EFSA Novel Food applications. By providing a non-medicinal supplement that emulates physiological responses to fasting and physical activity, the company aims to offer practical solutions for weight management, blood sugar regulation, and general wellness. Mmimetika is backed by scientific founders and strategic investors and is led by an experienced leadership team dedicated to global commercialization.
Inquire about this partnering listing
Industry applications
delivered to your inbox.